BT3:FRA
Lineage Cell Therapeutics Inc
€0.79
arrow_upward
+0.76%(+0.0060) 1D
Okt 15, 8:00:49 AM GMT+2 · EUR
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa BT3...
Buksan
€0.79
Mataas
€0.79
Mababa
€0.79
Mkt. cap
231.61M
Avg. na dami
37.00
Dami
0.00
Mataas nang 52-wk
€1.69
Mababa nang 52-wk
€0.78
Bilang ng mga empleyado
75
Buksan
€0.79
Mataas
€0.79
Mababa
€0.79
Mkt. cap
231.61M
Avg. na dami
37.00
Dami
0.00
Mataas nang 52-wk
€1.69
Mababa nang 52-wk
€0.78
Bilang ng mga empleyado
75
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
investingLive
·
12 oras ang nakalipas
S&P 500 decline extends to 100 points with tech hit particularly hard
Bloomberg.com
·
9 oras ang nakalipas
S&P 500 Ends Longest Streak of Calm Since 2020 as AI Trade Sinks
MarketWatch
·
1 buwan ang nakalipas
The S&P 500 keeps climbing on days when stocks broadly struggle. Here’s what’s going on.
Reuters
·
1 buwan ang nakalipas
S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Tungkol sa Lineage Cell Therapeutics Inc